• Explore /
  • Poster
  • / MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.

MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.

Abstract Poster

Authors

null

Marc S. Raab

Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany

Marc S. Raab , Manik Chatterjee , Hartmut Goldschmidt , Hermine Agis , Igor W Blau , Hermann Einsele , Monika Martha Engelhardt , Barbara Ferstl , Martin Gramatzki , Christoph Röllig , Katja Weisel , Pia Kloepfer , Dominika Weinelt , Jan Endell , Rainer Boxhammer , Christian Peschel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01421186

Citation

J Clin Oncol 34, 2016 (suppl; abstr 8012)

DOI

10.1200/JCO.2016.34.15_suppl.8012

Abstract #

8012

Poster Bd #

277

Abstract Disclosures

Similar Posters

First Author: James R. Berenson

First Author: Dan T. Vogl

First Author: Andrew J Yee

First Author: James D. Hilger